Weber, Manuel http://orcid.org/0000-0002-9000-1319
Pettersson, Olof
Seifert, Robert
Schaarschmidt, Benedikt M.
Fendler, Wolfgang P.
Rischpler, Christoph
Lahner, Harald
Herrmann, Ken
Sundin, Anders
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 26 July 2023
Accepted: 31 October 2023
First Online: 10 November 2023
Declarations
:
: MW reports fees from Advanced Accelerator Applications, Boston Scientific, Terumo, Eli Lilly. KH reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from Sirtex, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from Ipsen, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from Y-mAbs, personal fees from Aktis Oncology, and personal fees from Theragnostics, personal fees from Pharma15, outside the submitted work. WPF reports fees from Sofie Biosciences (research funding), Janssen (consultant, speakers bureau), Calyx (consultant), Bayer (speakers bureau), and Parexel (image review) outside of the submitted work. OP, CR, RS, and BS state that there is no conflict of interest. AS report fees from Advanced Accelerator Applications and IPSEN.